Compliance tip: Research your states Board of Medicine rules specific to weight loss and obesity treatmentgeneral dispensing compliance isnt enough
As research continues, GLP-1s therapeutic potential in AD remains a promising frontier ( Currently, the first randomized, double-blind phase III trial is underway to evaluate the effects of oral Semaglutide in AD prevention and progression
~6 days Half-Life (NEJM 2023) ~30 days Full Clearance (5 half-lives) 4-5 weeks Steady State Per Dose Once Weekly Dosing Interval Investigational Status Retatrutide is investigational and not FDA-approved as of April 2026
If your diet remains extremely calorie-dense despite reduced hunger, weight loss will be minimal
This article reviews the emerging trend of microdosing GLP-1 drugs, examining potential benefits, risks, and the current lack of scientific evidence supporting this approach
A reduction here means the medication is helping regulate your eating patterns
